ArticleJournal of medical biochemistry2026
Correlation analysis of serum cytokine levels and immune inflammatory factors in cirrhotic portal hypertension.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate alterations in immune-inflammatory factors and variables, including procalcitonin(PCT), prostaglandin E (PGE), and serum C-reactive protein (CRP) in individuals with cirrhotic portal hypertension. Methods: From March 2020 to March 2025, 81 patientswith cirrhotic portal hypertension and 50 healthy volunteerswere hospitalised to our hospital. These people were divided into two groups: the portal hypertension group and thecontrol group. Aspartate aminotransferase (AST), albumin(ALB), total bilirubin (TBIL), alanine aminotransferase(ALT), and portal vein inner diameter (Pvd) were measured.Serum cytokines, including CRP PCT, and PGE, weremeasured, as well as the percentages of CD 4+/CD 8+ Tcells and CD 3+ , CD 4+ , and CD8+ T lymphocytes. Results: The group with portal hypertension had considerablylower ALB than the control group (P< 0.05), whereas indicators including ALT, AST, TBIL, and Dpv were significantlyhigher in the portal hypertension group than in the controlgroup (P< 0.05). While cytokine markers, including CRPPCT, and PGE, were higher in the portal hypertension groupthan in the control group (P< 0.05), the numbers of CD3 +and CD4+ T lymphocyte subsets and CD4+/CD8+ T lymphocytes were considerably lower in the portal hypertensiongroup. With increasing liver function classification, the proportions of CD3+ and CD4+ T lymphocyte subsets, as wellas CD4+/CD 8+ T lymphocytes, decreased in patients. However, there was a statistically significant (P<0.05) increase in the levels of serum PCT, PGE, and CRP Spearmancorrelation analysis revealed that liver function classificationwas negatively correlated with immune indicators. CRP PCTand PGE levels were favourably connected with CD4+ andCD4+/CD 8+ values (P < 0.05). Dpv was shown to have anegative association with CD4+/CD8+ T cells and a positive correlation with PCT and PGE levels (P<0.05) accordingto Pearson correlation analysis. Conclusions: Patients with cirrhotic portal hypertensionmay experience immune dysfunction and cytokine disorders. These changes are related to liver function and portalvein pressure and can be used as reference indicators forevaluating a patient's condition in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.